Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial
Restricted accessResearch articleFirst published online September, 2024
Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial
Comorbid major depressive disorder (MDD) and opium use disorder (OUD) are known to increase the risk of suicide. The purpose of this study was to compare the efficacy and safety of adjunctive therapy with either ketamine or buprenorphine in patients with comorbid MDD and OUD.
Methods
This was a randomized double-blind controlled trial in adults admitted to a hospital in Iran. Sixty-six participants were enrolled and received either ketamine or buprenorphine, along with current antidepressant therapy. The primary outcome was change in depressive symptoms assessed using the Beck Depression Inventory (BDI) after 2 hours, 24 hours, and 7 days following initiation of treatment. Secondary outcomes included changes in suicidal ideation, evaluated by the Beck Scale for Suicidal Ideation (BSSI).
Results
Both groups experienced a significant decrease in the severity of depression following the interventions (p < .05). However, there was no significant difference in the between-group comparison (p > .05). Both groups also exhibited a significant reduction in suicidal ideation compared to before the study, with the decrease in severity being over 85% in both groups (p < .05).
Conclusion
Both ketamine and buprenorphine appear to be equally effective in reducing symptoms of depression and suicidal ideation among individuals with MDD and OUD.
KeshavarzKHedayatiARezaeiM, et al.Economic burden of major depressive disorder: a case study in Southern Iran. BMC Psychiatr. 2022;22(1):577.
2.
OtteCGoldSMPenninxBW, et al.Major depressive disorder. Nat Rev Dis Prim. 2016;2(1):16065.
3.
LépineJ-PBrileyM. The increasing burden of depression. Neuropsychiatric Dis Treat. 2011;7(sup1):3-7.
4.
CalarcoCALoboMK. Chapter Six - depression and substance use disorders: clinical comorbidity and shared neurobiology. In: CalipariESGilpinNW, eds. International Review of Neurobiology. Cambridge, MA, USA: Academic Press, 2021; 157:245-309.
5.
NiciuMJChanGGelernterJ, et al.Subtypes of major depression in substance dependence. Addiction. 2009;104(10):1700-1709.
6.
DavisLUezatoANewellJMFrazierE. Major depression and comorbid substance use disorders. Curr Opin Psychiatr. 2008;21(1):14-18.
7.
SharmaBBrunerABarnettGFishmanM. Opioid use disorders. Chil Adoles Psych Cli Nor Ame. 2016;25(3):473-487.
8.
WebsterLR. Risk factors for opioid-use disorder and overdose. Anesth Analg. 2017;125(5):1741-1748.
9.
JohnstonKMPowellLCAndersonIMSzaboSClineS. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195-210.
10.
AndrewANierenbergMDAmyFarabaughHMA, et al.Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatr. 2000;157(9):1423-1428.
11.
KasperSSpadoneCVerpillatPAngstJ. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol. 2006;21(2):105-110.
12.
MatveychukDThomasRKSwainsonJ, et al.Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Thera Advan Psych. 2020;10:2045125320916657.
13.
CameronCMNietoSBoslerL, et al.Mechanisms underlying the anti-suicidal treatment potential of buprenorphine. Adva Dru Alc Res. 2021;1:10009.
14.
AhmadiJ. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat. 2003;24(3):217-220.
15.
AhmadiJJahromiMSGhahremaniDLondonED. Single high-dose buprenorphine for opioid craving during withdrawal. Trials. 2018;19(1):675.
16.
AhmadiJRazeghian JahromiL. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017;18(1):259.
17.
AhmadiJ. A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug Alcohol Depend. 2002;66(2):111-114.
18.
AhmadiJ. Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. J Subst Abuse Treat. 2002;22(3):157-159.
19.
WuHSavaliaNKKwanAC. Ketamine for a boost of neural plasticity: how, but also when?Biol Psychiatr. 2021;89(11):1030-1032.
20.
ShulmanMWaiJMNunesEV. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567-580.
21.
AhmadiJBahramiN. Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. J Subst Abuse Treat. 2002;23(4):415-417.
22.
AhmadiJ. A randomized, clinical trial of buprenorphine maintenance treatment for Iranian patients with opioid dependency. Addict Disord Their Treat. 2002;1(1):25-27.
23.
AhmadiJAhmadiM. Twelve-month maintenance treatment of heroin-dependent outpatients with buprenorphine. J Subst Use. 2003;8(1):39-41.
24.
LutfyKCowanA. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2(4):395-402.
25.
DaleEBang-AndersenBSánchezC. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol. 2015;95(2):81-97.
26.
SerafiniGAdavastroGCanepaG, et al.The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018;19(8):2410.
27.
AhmadiJSefidfard JahromiM. Ultrarapid influence of buprenorphine on major depression in opioid-dependent patients: a double blind, randomized clinical trial. Subst Use Misuse. 2018;53(2):286-289.
28.
McCance-KatzEFSullivanLENallaniS. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4-16.
29.
ZarateCABrutscheNEIbrahimL, et al.Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatr. 2012;71(11):939-946.
30.
MurroughJWSoleimaniLDeWildeK, et al.Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571-3580.
31.
YovellYBarGMashiahM, et al.Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatr. 2015;173(5):491-498.
32.
AhmadiJSahraianABiusehM. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019;20(1):468.
33.
AhmadiJSaraniEMJahromiMS. Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: a randomized, double blind, placebo-controlled study. Tzu Chi Med J. 2020;32(1):58-64.
34.
LiWSunHChenH, et al.Major depressive disorder and kappa opioid receptor antagonists. Translational perioperative and pain medicine. 2016;1(2):4-16.
35.
CarlezonWABéguinCDiNieriJA, et al.Depressive-like effects of the κ-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Therapeut. 2006;316(1):440-447.
36.
LandBBBruchasMRLemosJCXuMMeliefEJChavkinC. The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. J Neurosci. 2008;28(2):407-414.
37.
ShippenbergTSBals-KubikRHerzA. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Therapeut. 1993;265(1):53-59.
38.
PhamTHGardierAM. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. Pharma Thera. 2019;199:58-90.
39.
AleksandrovaLRPhillipsAGWangYT. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatr Neurosci. 2017;42(4):222-229.
40.
GhosalSDumanCHLiuR-J, et al.Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents. Neurobiol Dis. 2020;134:104669.
41.
AsimMWangHWarisA. Altered neurotransmission in stress-induced depressive disorders: the underlying role of the amygdala in depression. Neuropeptides. 2023;98:102322.
42.
VuPDBansalVChitneniA, et al. Buprenorphine for chronic pain management: a narrative review. Curr Pain Headache Rep2023;28:1-10.
43.
AsimMWangBHaoBWangX. Ketamine for post-traumatic stress disorders and it's possible therapeutic mechanism. Neurochem Int. 2021;146:105044.
44.
KrausCWassermanDHenterIDAcevedo-DiazEKadriuBZarateCAJr. The influence of ketamine on drug discovery in depression. Drug Discov Today. 2019;24(10):2033-2043.
45.
FriesGRSaldanaVAFinnsteinJReinT. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatr. 2023;28(1):284-297.
46.
DakwarENunesEVHartCLHuMCFoltinRWLevinFR. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270-276.
47.
JonesJLMateusCFMalcolmRJBradyKTBackSE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatr. 2018;9:277.
48.
YoonGPetrakisILKrystalJH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatr. 2019;76(3):337-338.
49.
Elias DakwarMDEdwardNunesVMDCarlHartLPD, et al.A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatr. 2019;176(11):923-930.
50.
PradhanBRossiG. Combining ketamine, brain stimulation (rTMS) and mindfulness therapy (TIMBER) for opioid addiction. Cureus. 2020;12(11):e11798.
51.
KrupitskyEMGrinenkoAY. Ketamine psychedelic therapy (kpt): a review of the results of ten years of research. J Psychoact Drugs. 1997;29(2):165-183.
